Abstract
The activity of six cephalosporins, six penicillins and one monobactam combined with BRL 42715, clavulanic acid, sulbactam or tazobactam at 0.1, 0.5, 1, 2, 5 and 10 mg/L was determined for 45 beta-lactamase producing Gram-negative bacteria. The combination of BRL 42715 with any of the agents was more active than any of the other inhibitor and beta-lactam combinations. Unlike the other beta-lactamase inhibitors, BRL 42715 enhanced the activity of the beta-lactams for strains that constitutively expressed Richmond & Sykes Class I beta-lactamase and against strains expressing extended-spectrum plasmid-mediated beta-lactamases.
MeSH terms
-
Anti-Bacterial Agents / pharmacology*
-
Clavulanic Acid
-
Clavulanic Acids / pharmacology
-
Drug Therapy, Combination / pharmacology*
-
Enzyme Inhibitors / pharmacology
-
Gram-Negative Bacteria / drug effects*
-
Gram-Negative Bacteria / enzymology
-
Lactams*
-
Penicillanic Acid / pharmacology
-
Sulbactam / pharmacology
-
Tazobactam
-
beta-Lactamase Inhibitors*
-
beta-Lactamases / metabolism
-
beta-Lactams*
Substances
-
Anti-Bacterial Agents
-
Clavulanic Acids
-
Enzyme Inhibitors
-
Lactams
-
beta-Lactamase Inhibitors
-
beta-Lactams
-
C6-(N1-methyl-1,2,3-trazolylmethylene)penem
-
Clavulanic Acid
-
Penicillanic Acid
-
beta-Lactamases
-
Sulbactam
-
Tazobactam